Xenon Pharmaceuticals (XENE) Enterprise Value (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Enterprise Value data on file, last reported at -$1.1 billion in Q1 2026.

• On a quarterly basis, Enterprise Value fell 99.18% year-over-year to -$1.1 billion in Q1 2026; TTM through Mar 2026 was -$1.1 billion, a 99.18% decrease from a year earlier, with the FY2025 full-year figure at -$935.8 million, down 49.27% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.1 billion, down from -$935.8 million in the prior quarter.
• Over the last five years, Enterprise Value for XENE reached as high as -$526.7 million in Q3 2023 and fell as low as -$1.1 billion in Q1 2026.
• Historically, Enterprise Value has averaged -$703.5 million across 5 years, with a median of -$638.2 million in 2022.
• Across the five-year window, Enterprise Value slumped 202.56% in 2022 and surged 31.54% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$592.1 million in 2022, then slipped by 7.77% to -$638.1 million in 2023, then rose by 1.75% to -$626.9 million in 2024, then slumped by 49.27% to -$935.8 million in 2025, then fell by 16.99% to -$1.1 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$1.1 billion in Q1 2026, -$935.8 million in Q4 2025, and -$913.0 million in Q3 2025.